The Molecular Imaging Research of F-18 Labeled DX600 PET Probe
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04542863|
Recruitment Status : Not yet recruiting
First Posted : September 9, 2020
Last Update Posted : September 14, 2020
Angiotensin-converting enzyme 2 (ACE2) plays an important role in renin-angiotensin system (RAS) and has been reported to relate with cancer. Recently, it has also been proved as the key target for COVID-19 infection.
DX600 is a polypeptide that can specific binding to ACE2 specifically with nanomolar affinity reported in literature. This study constrcuted a radio-tracer, DX600 Labeled by PET Radionuclide, to monitoring biodistribution ACE2 in human beings, evaluate the detection ability of radio-tracer in ACE2 over-expression tumors and dynamic changes of ACE2 expression under therapy.
|Condition or disease||Intervention/treatment||Phase|
|Solid Tumor||Other: 18F-DX600 PET/CT||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Molecular Imaging Research of F-18 Labeled DX600 PET Probe|
|Estimated Study Start Date :||September 2020|
|Estimated Primary Completion Date :||September 2022|
|Estimated Study Completion Date :||September 2022|
Experimental: Imaging cohort
All study participants will be allocated to this arm (single-arm study). Study participants will undergo 18F-DX600 PET/CT scans.
Other: 18F-DX600 PET/CT
DX600, labeled with 18F will be used as a molecular imaging tracer for PET/CT scanning
- Standard uptake value (SUV) [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04542863
|Contact: Hua Zhufirstname.lastname@example.org|